Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARYAM KHAWARI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1346381365
CMS profile
1170349
Location
KATY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$81.13

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $81.13 6

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $29.19 2
Janssen Pharmaceuticals, Inc $26.77 2
GlaxoSmithKline, LLC. $14.04 1
GE HEALTHCARE $11.13 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARYAM KHAWARI

NPI 1346381365 · CMS profile ID 1170349

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

KATY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARYAM KHAWARI, NPI 1346381365, CMS profile ID 1170349. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARYAM KHAWARI, NPI 1346381365, CMS profile ID 1170349. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARYAM KHAWARI, NPI 1346381365, CMS profile ID 1170349, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1346381365?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $81.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $10.8611/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658524415 CMS
Janssen Pharmaceuticals, Inc $12.2309/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658837665 CMS
GE HEALTHCARE $11.1308/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698470313 CMS
Janssen Pharmaceuticals, Inc $14.5406/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658837661 CMS
Janssen Biotech, Inc. $18.3305/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658524409 CMS
GlaxoSmithKline, LLC. $14.0403/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671410499 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $81.13 6
PY2020 $44.18 3
PY2022 $151.16 8
PY2023 $671.99 31
PY2024 $581.78 24
PY2025 $739.86 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $602,203.64 55
PY2024 Principal investigator $249,711.62 17
PY2023 Principal investigator $51,621.05 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $292.92 12/31/2025 Non-covered Recipient Entity
WCG CLINICAL INC
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) No dispute reported 06/30/2026 1202532703
Principal investigator 1 ABBVIE INC. $700.00 12/31/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202535377
Principal investigator 1 ABBVIE INC. $2,050.00 12/04/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202528800
Principal investigator 1 ABBVIE INC. $2,592.10 12/04/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202529004
Principal investigator 1 ARGENX US, INC. $1,200.00 11/12/2025 Non-covered Recipient Entity
WCG Clinical Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161618
Principal investigator 1 Amgen Inc. $37,149.54 11/12/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246646489
Principal investigator 1 ABBVIE INC. $9,732.55 11/04/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520909
Principal investigator 1 ABBVIE INC. $3,800.00 10/30/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202519767
Principal investigator 1 ABBVIE INC. $5,605.60 10/09/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202515469
Principal investigator 1 ABBVIE INC. $4,295.00 10/09/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202515471
Principal investigator 1 ABBVIE INC. $1,985.00 08/05/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501272
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $20,150.00 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225335999
Principal investigator 1 Amgen Inc. $41,163.26 07/18/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome No dispute reported 06/30/2026 1246646484
Principal investigator 1 ABBVIE INC. $6,635.00 07/02/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202496283
Principal investigator 1 ABBVIE INC. $15,147.00 06/26/2025 Non-covered Recipient Entity
WCG CLINICAL INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202493149
Principal investigator 1 ARGENX US, INC. $77.40 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156337
Principal investigator 1 ARGENX US, INC. $3.15 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156341
Principal investigator 1 ARGENX US, INC. $13.25 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156344
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156348
Principal investigator 1 ARGENX US, INC. $1.75 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156353
Principal investigator 1 ARGENX US, INC. $238.75 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156356
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156359
Principal investigator 1 ARGENX US, INC. $143.20 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156363
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156367
Principal investigator 1 ARGENX US, INC. $5.60 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156372
Principal investigator 1 ARGENX US, INC. $477.50 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156377
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156380
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156385
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156389
Principal investigator 1 ARGENX US, INC. $132.50 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156392
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156395
Principal investigator 1 ARGENX US, INC. $155.25 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156400
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
R & H Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237156404
Principal investigator 1 ABBVIE INC. $3,500.00 06/12/2025 Non-covered Recipient Entity
WCG CLINICAL INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202491055
Principal investigator 1 Eli Lilly and Company $2,500.00 06/06/2025 Non-covered Recipient Entity
WCG CLINICAL INC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187893298
Principal investigator 1 ARGENX US, INC. $2,500.00 06/04/2025 Non-covered Recipient Entity
WCG Clinical Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161604
Principal investigator 1 ARGENX US, INC. $1,600.00 06/04/2025 Non-covered Recipient Entity
WCG Clinical Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161606
Principal investigator 1 ARGENX US, INC. $2,500.00 06/04/2025 Non-covered Recipient Entity
WCG Clinical Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161610
Principal investigator 1 ARGENX US, INC. $12,000.00 06/04/2025 Non-covered Recipient Entity
WCG Clinical Inc
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237161614
Principal investigator 1 ABBVIE INC. $663.00 05/22/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202485799
Principal investigator 1 Amgen Inc. $65,655.58 05/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246646480
Principal investigator 1 Amgen Inc. $16,372.44 05/21/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246647016
Principal investigator 1 ABBVIE INC. $200.00 05/06/2025 Non-covered Recipient Entity
WCG CLINICAL INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481467
Principal investigator 1 ABBVIE INC. $487.35 04/23/2025 Non-covered Recipient Entity
WCG CLINICAL INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202478679
Principal investigator 1 ABBVIE INC. $90.00 04/17/2025 Non-covered Recipient Entity
WCG CLINICAL INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202477596
Principal investigator 1 ABBVIE INC. $2,678.50 04/03/2025 Non-covered Recipient Entity
WCG CLINICAL INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202472397
Principal investigator 1 Amgen Inc. $255,084.79 04/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646497
Principal investigator 1 ABBVIE INC. $500.00 03/27/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202466778
Principal investigator 1 Amgen Inc. $15,204.04 03/19/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH-777 S FRY RD
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246647012
Principal investigator 1 ABBVIE INC. $200.00 03/06/2025 Non-covered Recipient Entity
WCG CLINICAL INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202457447
Principal investigator 1 ABBVIE INC. $413.20 02/13/2025 Non-covered Recipient Entity
WCG CLINICAL INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202451255
Principal investigator 1 ABBVIE INC. $3,786.75 02/05/2025 Non-covered Recipient Entity
WCG CLINICAL INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202445031
Principal investigator 1 Amgen Inc. $41,111.03 01/21/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246647024
Principal investigator 1 Amgen Inc. $17,604.49 01/15/2025 Non-covered Recipient Entity
R & H CLINICAL RESEARCH
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246647020
Principal investigator 1 ABBVIE INC. $2,678.50 01/02/2025 Non-covered Recipient Entity
WCG CLINICAL INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202434820